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Abstract
SVV infection of primates closely resembles VZV infection of humans. Like VZV, SVV becomes latent in ganglionic neurons. We used this
model to study the effect of immunosuppression on varicella reactivation. Cynomolgus monkeys latently infected with SVV were irradiated and
treated with tacrolimus and prednisone. Of four latently infected monkeys that were immunosuppressed and subjected to the stress of
transportation and isolation, one developed zoster, and three others developed features of subclinical reactivation. Another non-immunosuppressed
latently infected monkey that was subjected to the same stress of travel and isolation showed features of subclinical reactivation. Virus reactivation
was confirmed not only by the occurrence of zoster in one monkey, but also by the presence of late SVV RNA in ganglia, and the detection of
SVV DNA in non-ganglionic tissue, and SVV antigens in skin, ganglia and lung.
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Primary infection of humans by varicella zoster virus (VZV)
produces chickenpox (varicella), after which virus becomes
latent in ganglionic neurons along the entire neuraxis (LaGuardia
et al., 1999; Levin et al., 2003). Decades later, VZV reactivation
produces shingles (zoster). The development of zoster may be
viewed in the context of a continuum in immunodeficient
individuals, ranging from a natural decline in VZV-specific
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Attempts to produce disease by experimental infection of
animals with VZV have led to seroconversion without clinical
signs (Matsunaga et al., 1982; Myers et al., 1980, 1985;
Takahashi et al., 1975;Walz-Cicconi et al., 1986;Wroblewska et
al., 1982). Inoculation of VZVonto the cornea of mice leads to
the presence of viral DNA in ganglionic neurons and non-
neuronal cells, as well as in virtually every non-ganglionic organ
examined 1 month after infection (Wroblewska et al., 1993). In
guinea pigs, ocular (Tenser and Hyman, 1987) and subcutaneous
(Lowry et al., 1993) inoculation of VZV infection results in
ganglionic infection; VZValso infects isolated guinea pig enteric
ganglia in culture with features comparable to the physical state
of VZV nucleic acid and gene expression seen in latently
infected human ganglia (Chen et al., 2003). Rat ganglia also
become infected with VZV after experimental inoculation, and
1–3 months later, VZV DNA is present in both ganglionic
neurons and non-neuronal cells (Annunziato et al., 1998; Debrus
et al., 1995; Kennedy et al., 2001). Finally, another model which
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cient (SCID-hu) mice showed that ganglia become infected after
experimental inoculation (Zerboni et al., 2005). Unfortunately,
in vivo reactivation has not been shown in any of these animal
models.
Simian varicella virus (SVV) infection of primates has
provided a useful animal model of varicella latency and
pathogenesis in humans. After natural infection in primates,
SVVreactivates spontaneously (Soike et al., 1984; Soike, 1992).
Evidence for SVV reactivation has been observed in monkeys
exposed to social and environmental stress (Soike et al., 1984).
Both the 1968 and 1974 outbreaks of varicella in Erythrocebus
patas monkeys at the Tulane National Primate Research Center,
Covington, LA, were attributed to reactivation of SVV (Soike,
1992). Although VZV reactivation in humans (zoster) is
generally localized to 1–3 dermatomes, SVV reactivation
often appears as a whole-body rash. Zoster in monkeys may
be obscured by fur, and the duration of rash is generally less than
1 week. VZV has been isolated from zoster lesions (Weller,
1958), and SVV has been isolated from skin vesicles after
reactivation (Soike et al., 1984). In their respective immuno-
competent hosts, VZV and SVV have not been isolated from
blood. The prevalence of SVV infection in monkeys in the wild
is unknown. We have reproduced natural SVV infection in
monkeys by contact exposure of SVV-seronegative monkeys to
other monkeys that had been inoculated intratracheally with
SVV (Mahalingam et al., 2002). These naturally infected
monkeys harbor latent SVV in ganglionic neurons (Kennedy
et al., 2004).
The frequency of VZV reactivation is related to the intensity
of immunosuppression, with a higher incidence in patients
receiving chemotherapy combined with radiotherapy than in
those receiving either alone (Mandal, 1987). These clinical
observations underline the need to dissect the relative role of X-Fig. 1. Experimental design. Seven cynomolgus monkeys (#1–7) were exposed to oth
monkeys developed varicella rash 10–14 days after exposure. 3 months post-exposure
SVV DNA. At 7 months post-exposure (7 m), four monkeys (#3–6) received one
Materials and methods. 2 weeks after irradiation, monkey #3 developed a zoster ra
respectively. Monkey #7 was neither irradiated nor treated with tacrolimus and predirradiation, immunosuppression or anti-inflammatory steroid
therapy in varicella reactivation. Earlier, we described sub-
clinical reactivation of latent SVV from asymptomatic irra-
diated rhesus macaque monkeys leading to disseminated
varicella in a seronegative irradiated monkey in the same
colony (Kolappaswamy et al., 2007). However, in that study,
ganglionic and non-ganglionic tissues from the monkeys with
subclinical reactivation were not available for analysis of virus
DNA, RNA or protein.
Herein, we established latent SVVinfection by natural contact
exposure to virus (Mahalingam et al., 2002), and treated them
with immunosuppressive regimens used for human bonemarrow
transplant recipients.
Results
Establishment of SVV latency
To determine if SVV latency can be established in cyno-
molgus monkeys, seven SVV-seronegative monkeys (#1–7)
were exposed to other monkeys previously inoculated intra-
tracheally with 104 PFU of SVV as described (Mahalingam et
al., 2002) (Fig. 1). All seven monkeys developed varicella rash
10–14 days later. DNAwas extracted from the area of rash from
monkey #1 and analyzed by PCR in triplicate. SVV infection
was confirmed by detection of SVV ORF 63 DNA sequences in
3/3 PCRs (Fig. 2A).
Three months post-infection, monkeys #1 and 2 were
euthanized. Total DNA was extracted from pooled trigeminal,
cervical, thoracic, lumbar and sacral ganglia, as well as from
liver and lung from monkeys #1 and 2. PCR was performed
in triplicate because the latent SVV DNA burden is very low.
In monkey #1, latent SVV DNA was detected in pooled
cervical (1/3), thoracic (1/3) and lumbar (3/3) ganglia but noter monkeys previously inoculated intratracheally with SVV (104 PFU). All seven
(3 m), monkeys #1 and 2 were euthanized and multiple tissues were analyzed for
dose of X-irradiation followed by tacrolimus and prednisone as described in
sh. Monkeys #3–6 were euthanized 9–12 months post-exposure (9 m–12 m),
nisone and was euthanized 12 months post varicella.
Fig. 2. Establishment of latent SVV infection in ganglia of cynomolgus monkeys. Nested PCR followed by Southern blot hybridization using a radiolabeled SVVORF
63-specific probe revealed SVV DNA in DNA extracted from scrapings of rash from monkey #1 at 14 days after natural exposure to SVV (A), in multiple ganglia of
both monkeys #1 and 2 (B), but not in lung or liver (C). All PCR products were performed in triplicate. In each set of reactions, DNAwas omitted from one of the tubes
(no DNA). DNA extracted from uninfected (BSC-1) and SVV-infected (SVV–BSC-1) BSC-1 cells in culture were used as negative and positive controls, respectively.
52 R. Mahalingam et al. / Virology 368 (2007) 50–59in trigeminal (0/3) or sacral (0/3) ganglia. In monkey #2, latent
SVV DNAwas detected in pooled cervical (2/3) and sacral (1/3)
ganglia but not in trigeminal (0/3), thoracic (0/3) or lumbar (0/3)
ganglia. SVV DNAwas not detected lung (0/3) or liver (0/3) of
monkeys #1 and 2 (Figs. 2B and C). Our sensitivity of detection
is 1 copy per μg of DNA (White et al., 2002). Because we assay
1 μg of ganglionic DNA in triplicate, the detection of SVV
DNA in 1/3 samples translates to less than 1 copy of SVV DNA
per μg of ganglionic DNA. The presence of SVV DNA in
ganglia, but not in viscera, confirmed the establishment of latent
infection.Fig. 3. Immunosuppression of cynomolgus monkeys latently infected with SVV. W
intervals post-irradiation from monkeys #3–6. All four monkeys received a single dos
prednisone (2 mg/kg/day). For the first 4 weeks, tacrolimus and prednisone were give
(open triangle), when drug was given daily. Average WBC values along with stan
presented (open squares). WBC count was also determined in the latently infected
Decreased WBCs were found in all drug-treated monkeys.Effect of immunosuppression on monkeys white blood cell
(WBC) counts and serology in monkeys
To determine the effect of treatment using a combination of
X-irradiation, immunosuppressive and anti-inflammatory drugs
on monkeys latently infected with SVV, 7 months after
developing varicella, monkeys #3–6 were irradiated and
treated with tacrolimus and prednisone as described in
Materials and methods. WBC counts were obtained weekly
(Fig. 3). During the next 4 weeks, the number of WBCs in
monkey #7 remained constant. 1 week post-irradiation, allhite blood cell (WBC) counts (normal 7–15×103/μl) were obtained at weekly
e (200 cGy) of X-irradiation (week 1) followed by tacrolimus (80 μg/kg/day) and
n daily. At 4 weeks (dark triangle), drugs were given every other day until week 8
dard errors for monkeys treated with immunosuppressive regimen (# 3–6) are
monkey #7 that was not treated with immunosuppressive drugs (dark squares).
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count in the four immunosuppressed monkeys (#3–6) dropped
to about 5000 and continued to decline further in the next
3 weeks. When the dosage of tacrolimus and prednisone was
switched to every other day for a 4-week period, the average
WBC count increased to about 9000. At 8 weeks post-
irradiation, tacrolimus and prednisone were again given daily,
and the WBC count remained high in all monkeys. Overall,
immunosuppression produced a transient but substantial
reduction in WBC count.
Table 1 gives serological data on monkeys #3–7. Serum
obtained before varicella revealed no anti-SVV antibody.
30 days after varicella rash, anti-SVV antibodies were still not
detected in monkeys #3 and 5. Sera from three monkeys (#4, 6
and 7) contained antibody to SVVat a dilution of 1:40, 1:20 and
1:40, respectively. Serum from the positive control monkey
inoculated intratracheally with SVV contained antibody at a
dilution of 1:320. After immunosuppression, SVV antibodies
were not detected in monkeys #3 and 5; in monkeys #4 and 6,
SVV antibody titers were 1:40 and 1:10, respectively. At
necropsy, in monkey #7, SVV antibody titer was 1:20. Three
naturally infected monkeys (# 4, 6 and 7) seroconverted after
varicella. Anti-SVV antibody titers did not correlate with
immunosuppression.
Detection of SVV DNA in peripheral blood mononuclear cells
(MNCs)
We detected SVV DNA by nested DNA PCR in DNA
extracted from MNCs from monkeys #4–6 at days 7, 105 and
62 post-immunosuppression, respectively.
Detection of SVV DNA and RNA in ganglionic and
non-ganglionic tissues
After skin, lungs and liver are the most common organs
affected during primary infection; thus, we searched for SVV
DNA in these non-ganglionic tissues as well as for late viral
transcripts in ganglia. The presence of SVV DNA in viscera or
SVV RNA corresponding to late genes in ganglia wouldTable 1
Antibody response to SVV infection and immunosuppression in cynomolgus
monkeys a
Monkey no. Before varicella After varicella b After immunosuppression c
3 b1:10 b1:10 b1:10
4 b1:10 1:40 1:40
5 b1:10 b1:10 b1:10
6 b1:10 1:20 1:10
7 d b1:10 1:40 NAe
Positive f b1:10 1:320 NA
a Anti-SVVantibody titers are expressed as the serum dilution that neutralized
80% or more of the SVV plaques compared to control cultures.
b Sera obtained 30 days after varicella rash.
c Sera obtained at necropsy.
d Not immunosuppressed; titer on necropsy was 1:20.
e Not applicable (no immunosuppression).
f Intratracheally inoculated with SVV.indicate virus reactivation. In the four immunosuppressed
monkeys, SVV ORF 63 DNAwas detected in lung of monkeys
#4 and 6 and in liver from monkey #6. SVV ORF 63 DNAwas
detected in both lung and liver from immunosuppressed
monkey #6 and in monkey #7 (Table 2) indicating subclinical
reactivation. SVV ORF 63 DNAwas detected in lumbar ganglia
of all four immunosuppressed monkeys, in trigeminal ganglia
from two immunosuppressed monkeys (#3 and 4), in cervical
and thoracic ganglia from immunosuppressed monkeys #4 and
6, and in sacral ganglia from immunosuppressed monkeys #3, 4
and 6. In monkey #7, SVV ORF 63 DNA was detected in
ganglia from multiple dermatomes.
We studied VZV ORF 63 transcripts because ORF 63 is the
most frequent and abundantly transcribed VZV gene in latently
infected human ganglia (Cohrs and Gilden, 2007), as well as
ORFs corresponding to one early (ORF 28) and 2 late (ORFs 40
and 9) viral genes. RT–PCR analysis of SVV DNA-positive
ganglia from monkeys #1 and 2 latently infected with SVV did
not detect virus-specific transcripts. SVV ORF 63-specific
transcripts were detected in at least one ganglion from two of
four immunosuppressed monkeys (#4 and 6) as well as in
monkey #7. No SVV ORF 28-specific transcripts were detected
in any ganglia. Transcripts specific for SVV ORF 40 were
detected in sacral ganglia from immunosuppressed monkey #4.
SVV ORF 9-specific transcripts were detected in thoracic
ganglia from monkey #4 and in sacral ganglia from immuno-
suppressed monkey #6. The detection of transcripts specific for
capsid protein (SVV ORF 40) and a tegument protein (SVV
ORF 9) in ganglia in the absence of rash indicates subclinical
reactivation. Transcripts specific for SVV ORFs 40 or 9 were
not detected in ganglia of monkey #7. Since the sensitivity of
our detection of SVV DNA by PCR is 1 copy and by RT–PCR
is 10 copies (White et al., 2002), lack of detection of SVV DNA
or RNA in any sample indicates a low abundance.
Detection of SVV glycoproteins in ganglionic and
non-ganglionic tissues
Two weeks after irradiation and drug treatment, monkey #3
developed disseminated zoster as evidenced by the develop-
ment of lesions in the right axilla and left medial thigh. Virus
reactivation is likely to result in the production of replicating
virus particles whose presence can be confirmed by the
detection of virus glycoproteins. Therefore, we analyzed
sections obtained by punch biopsy from the area of rash using
immunohistochemistry with antibodies specific for SVV
glycoproteins gH and gL. SVV antigen was detected in the
necrotic skin of the monkey (Fig. 4 and Table 2). No other
monkeys developed zoster. Histological exam of lung and liver
from monkey #3 did not reveal any pathological changes. SVV
glycoproteins were detected in lung (Fig. 5) from three (#3, 4
and 6) of four immunosuppressed monkeys and also in monkey
#7 (Table 2). Figs. 5A and C show positive staining in the
alveoli (monkey #3) and columnar cells within the bronchiolar
wall (monkey #6), respectively. We extracted RNA from
random portions of lung (different from the portion of lung
that was fixed) of all 5 monkeys. We first showed that the RNA
Table 2
Detection of SVV DNA, RNA and glycoprotein in monkey tissues
Treatment Monkey
no.
Tissue a DNA PCRb cDNA PCRc IHCd
(gH+gL)
63 Actin 63 28 40 9 Actin
Immunosuppression 3 Lung − + NDe ND ND ND ND +
Liver − + ND ND ND ND ND −
TG + + − − − − + ND
Cervical − + ND ND ND ND ND ND
TH − + ND ND ND ND ND ND
Lumbar + + − − − − + ND
Sacral + + − − − − + ND
Skin ND ND ND ND ND ND ND +
4 Lung + + ND ND ND ND ND +
Liver − + ND ND ND ND ND −
TG + + − − − − + ND
Cervical + + + − − − + −
TH + + + − − + + +
Lumbar + + + − − − + +
Sacral + + − − + − + +
5 Lung − + ND ND ND ND ND −
Liver − + ND ND ND ND ND +
TG − + ND ND ND ND ND ND
Cervical − + ND ND ND ND ND ND
TH − + ND ND ND ND ND ND
Lumbar + + − − − − + ND
Sacral − + ND ND ND ND ND ND
6 Lung + + ND ND ND ND ND +
Liver + + ND ND ND ND ND −
TG − + ND ND ND ND ND ND
Cervical + + + − − − + +
TH + + − − − − + ND
Lumbar + + − − − − + ND
Sacral + + + − − + + +
No immunosuppression 7 Lung + ND ND ND ND ND ND +
Liver + + ND ND ND ND ND −
TG + + − − − − + ND
Cervical + + − − − − + ND
TH + + + − − − + −
Lumbar + + + − − − + +
Sacral + + − − − − + ND
a TG=trigeminal ganglia; TH=thoracic ganglia; skin=area of skin rash.
b Primers specific for SVV ORF 63 or actin were used in PCR.
c Primers specific for SVV ORFs 63, 28, 40, 9 or actin were used in PCR portion of RT–PCR.
d Immunohistochemistry.
e ND=not done.
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(data not shown). No SVV specific transcripts were found. SVV
antigen was also found in liver from one immunosuppressed
monkey (#5), but not in monkey #7 which was not treated with
the immunosuppressive regimen (Table 2).
Immunohistochemical analysis of ganglia located on the side
of the neuraxis (Fig. 6) opposite to ganglia containing SVV
transcripts revealed SVV glycoproteins in the cytoplasm of
several neurons in thoracic ganglia from monkey #4 (Fig. 6A).
Absence of SVV antigens in some neurons in the same section
(Fig. 6A, thin arrow) and in all neurons in an adjacent section
analyzed using normal rabbit serum (Fig. 6B) confirmed the
specificity of detection of viral antigens. SVV glycoproteins
were also detected in axons in lumbar ganglia from monkey #4
(Fig. 6C). No SVV glycoproteins were detected in thoracic or
lumbar ganglia from a latently infected monkey (Figs. 6E and F).Overall, SVV glycoproteins were detected in one or more
ganglia from two of four immunosuppressed monkeys as well
as in monkey #7 (Table 2). The detection of SVV glycoproteins
in ganglionic as well as non-ganglionic tissues in monkeys #4,
6 and 7 indicates subclinical reactivation.
Discussion
Of four monkeys that were latently infected with SVV,
immunosuppressed and subjected to the stress of transportation
and isolation, one developed zoster and the other three showed
possible subclinical reactivation. Another monkey that was
latently infected with SVV and not immunosuppressed, but
subjected to the same stress of travel and isolation, also showed
possible subclinical reactivation. Virus reactivation was con-
firmed by the development of zoster in one monkey, and by the
Fig. 5. Detection of SVV glycoproteins in lungs from immunosuppressed
monkeys. Immunohistochemistry using rabbit polyclonal antibodies against
SVV glycoproteins H and L shows viral antigens in alveoli and columnar cells
from immunosuppressed monkey #3 (A) and #6 (C). Staining with normal rabbit
serum showed no such staining in adjacent sections (B and D). No virus antigen
was detected using rabbit polyclonal antibodies against SVV glycoproteins H
and L in lung columnar epithelium from a monkey latently infected with SVV
that was not immunosuppressed (E).
Fig. 4. Detection of SVV glycoproteins in skin from a monkey with zoster.
Immunohistochemistry using rabbit polyclonal antibodies against SVV
glycoproteins H and L reveals viral antigens in skin from area of zoster in
monkey #3 (A), but not with normal rabbit serum (B). The rabbit polyclonal
antibodies against SVV glycoproteins H and L did not detect any viral antigens
in normal skin from a latently infected monkey (C).
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presence of SVV RNA specific for late capsid proteins (ORFs
40 and 9) in ganglia, and SVV antigens in skin, ganglia,
including axons, and viscera. We have searched for, but have
not found SVV 40 and 9 transcripts in latently infected monkey
ganglia (unpublished observations). So far, SVV latency seems
to parallel VZV latency at a molecular level.
Fig. 6. Detection of SVV glycoproteins in ganglia from immunosuppressed monkeys. Immunohistochemistry using rabbit polyclonal antibodies against SVV
glycoproteins H and L shows viral antigens in thoracic (A) and lumbar (C) ganglia samples from immunosuppressed monkey #4; normal rabbit serum showed no such
staining in the adjacent sections (B and D, respectively). No virus antigen was detected using rabbit polyclonal antibodies against SVV glycoproteins H and L in
thoracic ganglia (E) or lumbar ganglia (F) from a monkey latently infected with SVV. Thick and thin arrows in (A) indicate SVV antigen-positive and -negative
neurons, respectively. Arrowhead in (C) indicates SVV antigen-positive axons.
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restricted to skin. It is possible, if not likely, that virus
reactivation results in infection of other organs, particularly
lung and liver, without clinical symptoms or signs. Our
detection of SVV in these organs during reactivation provides
support for such a notion, and indicates the value of the SVV
model as a good one for human VZV reactivation.
Ideally, it would have been useful to show the presence of
SVV RNA and antigens in the same ganglia. While it is possible
to combine ISH and immunohistochemistry in paraformalde-
hyde-fixed tissue sections, reproducibility is difficult when RNA
or antigen is low abundance. Thus, we analyzed RNA from
frozen ganglia on one side of the neuraxis and SVV antigens
from fixed ganglia of the other side. While we found SVV DNA
or antigens in lungs from all monkeys and SVV DNA or antigen
in liver from some monkeys, we did not detect virus specific
transcripts in lung or liver. We believe this most likely reflects
sampling. For example, even SVV glycoproteins were only seen
in a small (b5%) area of the entire section of lung (Fig. 5). Thus,
despite not finding SVV RNA in some organs outside the
ganglia, SVV reactivated in every monkey based on the
demonstration of SVV late transcripts in ganglia as well as by
the presence of SVV DNA or proteins in non-ganglionic tissues.
Our detection of possible subclinical SVV reactivation in
primates was not surprising since subclinical VZV reactivation
has been well documented in human solid organ transplant
recipients (Kronenberg et al., 2005) as well as in healthy adult
astronauts (Mehta et al., 2004). In bone marrow transplantrecipients, subclinical reactivation was demonstrated by a rise in
VZVantibody titer and an increase in VZV-specific lymphocyte
proliferation (Ljungman et al., 1986; Luby et al., 1977).
Accordingly, we also found anti-SVV antibody in some
monkeys with subclinical reactivation, although the titer was
low. The low titer of anti-SVV antibody in some monkeys as
well as the lack of SVVantibody in others is surprising since we
readily detect anti-VZV antibody in humans. We do not know
why SVV antibody is so difficult to detect in latently infected
immunosuppressed monkeys, but do not believe it is a technical
problem since we readily detect SVV antibody in monkeys
which have been inoculated intratracheally with SVV (Maha-
lingam et al., 1991). We do not think age is a factor in low
antibody production since all the monkeys we used were in the
prime of life (young adults). With varicella, cell-mediated
immunity appears to be more important than humoral immunity
(Quinlivan and Breuer, 2006), probably because spread of virus
within the body is intracellular. The contribution of the humoral
response to infection is limited (Abendroth and Arvin, 2001),
and the absence of antibodies does not rule out diagnosis
(Heininger and Seward, 2006). Our future studies will include
analysis of antigen specific T-cell expansion, which should not
only confirm subclinical reactivation, but also explain the lack
of detection of a strong humoral immunity. Finally, our
occasional detection of SVV DNA in blood mononuclear
cells (MNCs) of monkeys in this study also supports subclinical
reactivation. VZV DNA has been found in MNCs of elderly and
immunocompromised individuals (Schunemann et al., 1998).
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demonstrated sub-clinical reactivation of latent SVV in an
asymptomatic irradiated rhesus macaques. As a result of virus
reactivation in the monkey, another seronegative monkey which
had been irradiated developed disseminated varicella 105 days
later. Unfortunately, ganglia from the monkey, which reacti-
vated subclinically, were not available for analysis. Thus, in the
current study, we extended treatment of latently infected
monkeys to tacrolimus and prednisone and also subjected
them to stress of transportation and isolation. Tissue was also
studied more extensively for virus-specific DNA, RNA and
protein, underlining the need to compare immunosuppression
with the role of stress in virus reactivation. Future experiments
will separate each immunosuppressive regimen. Finally, the
SVV reactivation protocol described in this study may be useful
in testing preventive vaccination, antiviral drugs, SVV strain
differences, age factors and other variables.
Materials and methods
Monkeys
3- to 4-year-old SVV-seronegative cynomolgus monkeys
(Macaca fascicularis) housed in the Tulane National Primate
Research Center in Covington, LAwere used in all experiments.
Monkeys were transported across Lake Pontchartrain in a van
(1-h ride) to the Tulane University Cancer Center in New
Orleans, LA, for subsequent anesthesia and irradiation. One
monkey was not irradiated, but was subjected to the same stress
of transportation and anesthesia.
Establishment of latent virus infection
SVV (Delta herpesvirus strain) isolated from a naturally
infected monkey (E. patas) was propagated in Vero cells, and a
virus stock was prepared as described (Mahalingam et al.,
1992). Seven SVV-seronegative cynomolgus monkeys were
exposed to other cynomolgus monkeys that had been inoculated
intratracheally with 104 plaque-forming units (PFU) of SVV, as
described (Mahalingam et al., 1991). All monkeys were
examined daily and blood was obtained once weekly. In all
seven monkeys, a mild varicella rash developed 10–14 days
later. At this time, the area of skin rash from monkey #1 was
scraped and studied by PCR for SVV DNA. Three months later,
monkeys #1 and 2 were euthanized and ganglionic and non-
ganglionic tissues were harvested and snap-frozen in liquid
nitrogen for DNA analysis. All procedures were performed
following appropriate guidelines and protocols approved by the
Institutional Animal Care and Use Committee.
Immunosuppressive regimens
X-irradiation
Seven months after natural SVV infection, all monkeys were
anesthetized intramuscularly (IM) with telazol (tiletamine/
zolazepam) (8 mg/kg). In addition, before and after irradiation,
all animals were treated (IM) with zofran (ondansetron)(0.1 mg/kg) to prevent nausea and vomiting that often develops
after chemotherapy and irradiation. Monkeys #3–5 were given
total body irradiation consisting of 200 cGy delivered at a dose
rate of b20 cGy/min using a megavoltage irradiation beam
(6 MV X-rays) for 10–20 min. Half the dose was delivered with
the animal supine and half with the animal prone. Monkey #7
was similarly anesthetized, but not irradiated.
Tacrolimus treatment
Seven months after natural exposure to SVV (immediately
after X-irradiation), monkeys #3–6 were treated orally with
500 μg daily (80 μg/kg/day) of prograf (tacrolimus) for 4 weeks
followed by every other day for 4 weeks, and then switched back
to daily dosage until they were euthanized (Fig. 1). Tacrolimus is
a potent immunosuppressive drug that suppresses humoral
immunity and to a greater extent cell-mediated immunity.
Prednisone treatment
Seven months after natural exposure (immediately after X-
irradiation), monkeys #3–6 were also treated orally with 5 mg
daily (2 mg/kg/day) of prednisone every day for 4 weeks
followed by every other day for 4 weeks, and switched back to
daily treatment until they were euthanized (Fig. 1). Prednisone is
a steroid medication with a strong anti-inflammatory effect.
Monkey #7 was not irradiated or treated with drugs. All
monkeys were observed daily for zoster rash. Monkeys #3–5
were euthanized at 9, 10 and 11 months after varicella. Monkeys
#6 and 7 were euthanized 12 months after varicella. Lung and
liver tissues were harvested and divided into two portions. One
portion was snap-frozen for DNA extraction. The other portion
was fixed in 4% paraformaldehyde and paraffin-embedded.
Ganglia on the two sides of the neuraxis were kept separately.
Ganglia from each dermatome were pooled. Pooled ganglia
from specific dermatomes and from one side of the neuraxis
were snap-frozen in liquid nitrogen, while pooled ganglia from
the same dermatomes of the other side of the neuraxis were
fixed in 4% paraformaldehyde and paraffin-embedded. Under
anesthesia, monkey #3 was punch-biopsied in the area of zoster
rash and the sample was fixed in 4% paraformaldehyde and
paraffin-embedded.
Plaque reduction assay for anti-SVV antibody
Anti-SVVantibody titers in serum obtained from all monkeys
were determined using a plaque reduction assay (Soike et al.,
1991). Serum from a monkey that had been inoculated intra-
tracheally with SVV served as a positive control.
DNA and RNA isolation
DNAwas extracted from African green monkey kidney cells
(BSC-1) infected with SVV and from medium containing the
skin rash scrapings using a QIAamp blood mini-kit (Qiagen,
Valencia, CA). DNA was also extracted from MNCs using the
blood DNA extraction kit (Qiagen). Total DNA was extracted
from individual or pooled trigeminal, cervical, thoracic, lumbar
and sacral ganglia, as well as from liver and lung, using a
58 R. Mahalingam et al. / Virology 368 (2007) 50–59DNeasy Tissue kit (Qiagen) according to the manufacturer's
instructions. Total RNA was extracted from ganglia (that were
positive for SVV DNA) and treated with DNase as described
(White et al., 2002).
DNA and RT–PCR
Oligonucleotide primers (Integrated DNA Technologies,
Coralville, IA) and probes specific for SVV ORF 63 were
used to amplify and detect SVV DNA as described (White et al.,
2002). All PCRs were nested. DNA (1 μg) extracted from tissue
was scored as positive if it was detected in at least one of three
PCRs. Every PCR and nested PCR included negative controls
(no added DNA and DNA from uninfected cells), and positive
controls (DNA from SVV-infected cells). Furthermore, in each
RT–PCR reaction, we include a negative and positive RT
control. SVV ORF-specific and actin-specific oligonucleotides
used in reverse transcription and the RT–PCR procedure have
been described (White et al., 2002).
Immunohistochemistry
Sections (5 μm) of lung, liver or ganglia were analyzed for the
presence of SVV antigen by immunohistochemistry (Mahalin-
gam et al., 1996) using a 1:500 dilution of normal rabbit serum or
a mixture of polyclonal anti-peptide antibodies raised in rabbits
against SVV glycoproteins H and L (Ashburn and Gray, 2002).
Each immunohistochemistry experiment was repeated at least 3
times.
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